Which groups benefited most from an ECHELON-1 approach?
Professor Stephen Ansell (Mayo Clinic, USA) discusses who might benefit most from A+AVD upfront in HL. Interview by Esther Drain.
Professor Stephen Ansell (Mayo Clinic, USA) discusses who might benefit most from A+AVD upfront in HL. Interview by Esther Drain.
Professor Anas Younes (MSKCC, New York), Professor John Radford (Manchester) and Dr Graham Collins (Oxford). Interviews by Esther Drain. Once again ASH provided much food for thought and above leading experts discuss their… read more.
Article written by Tom Collins. Interviews by Esther Drain. Trying to usher new immunotherapies into the setting of non-Hodgkin lymphomas (NHL) has been met with mixed results, and… read more.
Article written by Tom Collins. Interviews by Esther Drain. Replacing bleomycin with brentuximab vedotin (A+AVD) in the traditional regimen for previously untreated Hodgkin lymphoma patients significantly improved modified… read more.
Article written by Tom Collins. Interview by Esther Drain. Even as definitions of risk groups in myeloma become more sophisticated, a reasonable way to assess those patients with… read more.
Cure is not simply about having a few patients cured – it’s about reliably being able to cure a population with a disease, argues Professor S Vincent Rajkumar (Mayo Clinic,… read more.
Professor Stephen Ansell (Mayo Clinic, USA) speaks about harnessing the power of immunotherapy in Non Hodgkin’s Lymphoma.
by Maria Dalby Effective treatment options for perianal fistulas constitute a major unmet need in Crohn’sdisease (CD). New interventions included a knot-free silicon drain to replace conventional setons, and a circular blade… read more.
ESCP 2017 delegates give their highlights, plus a report on the ESCP/ECCO symposium on ulcerative colitis and a focus on quality of life for patients with perianal Crohn’s disease.
Author: Bruce Sylvester Patients with persistent symptomatic asthma had fewer asthma exacerbations and improved quality of life when treated with oral azithromycin for 48 weeks, researchers on August… read more.
By Maria Dalby (article) and Peter Mas Mollinedo (interviews) The decision to perform a colectomy in patients with ulcerative colitis (UC) should not be made lightly. Such a… read more.
Author: Bruce Sylvester Exenatide, a drug used to treat diabetes, could have disease-modifying potential in the treatment of Parkinson’s disease, researchers reported on August 3, 2017 in The… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.